

February 23, 2015

Announcement of an agreement with Shionogi & Co., Ltd. on Phase III clinical trial of
the cancer-specific peptide vaccine S-588410

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that OncoTherapy and Shionogi & Co., Ltd. (Head office: Chuo-ku, Osaka, President and CEO: Isao Teshirogi, hereinafter “Shionogi”) have agreed (hereinafter, the “Agreement”) today on Phase III clinical trial of the cancer-specific peptide vaccine S-588410, which OncoTherapy has out-licensed to Shionogi, for esophageal cancer, for collaborative effort on the clinical development of S-588410.

1. Summary of the Agreement

- (1) Shionogi will conduct a multicenter, randomized, double-blind, placebo-controlled, comparative Phase III clinical trial of S-588410 as adjuvant therapy for esophageal cancer (hereinafter, the “Clinical Trial”).
- (2) OncoTherapy and Shionogi will modify the milestone setting in the Clinical Trial that was defined by the license agreement between both parties on March 29, 2012, and OncoTherapy will receive from Shionogi development milestone payments defined by the Agreement according to the progress stage of the Clinical Trial.
- (3) OncoTherapy will pay for part of the expenses of the Clinical Trial.